all the preclinical stuff is proving to be very comprehensive and a significant body of work that is hard to ignore.
would be great to get a little feedback from the Chiam Sheba trial as this is currently the only clinical stage trial actually underway
as others have commented previously, sophisticated investors do not place too much substance on lab results/ mice etc
results from this study, however limited, might help to get the price to where it needs to be for the options to be worthwhile (and the subsequent revenue needed from them for additional trials)
Ann: Preclinical & Clinical Programs Update, page-12
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.94 |
Change
0.055(2.92%) |
Mkt cap ! $330.4M | |||
| Open | High | Low | Value | Volume |
| $1.89 | $1.96 | $1.85 | $333.0K | 174.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3105 | $1.94 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.95 | 7574 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |